Editas Medicine holds 2026 annual meeting; elects two Class I directors and ratifies auditor

The Company’s stockholders approved, on an advisory basis, the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 32,914,258 6,322,885 212,587 26,404,190

The Company’s stockholders elected Bernadette Connaughton and Elliott Levy, M.D., to serve as Class I directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows: Votes For Votes Withheld Broker Non-Votes Bernadette Connaughton 28,660,181 10,789,549 26,404,190 Elliott Levy, M.D. 37,095,058 2,354,672 26,404,190

The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 64,686,839 774,471 392,610 0